Abstract 146P
Background
This meta-analysis collected studies with propensity score matching analysis (PSM) or Randomized Controlled Trial(RCT) and focused on comparing the short-term and oncological outcomes of patients with HCC who underwent anatomic liver resection (AR) versus non-anatomic liver resection (NAR), to provide relatively high-level evidence of AR in treating patients with HCC in comparison with NAR.
Methods
A systematic literature search was performed using the PubMed, Embase, Cochrane Library and Web of Science to identify studies comparing AR with NAR by June 2019. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of the research included. The data were analyzed using Review Manager (Version 5.3). Dichotomous data were calculated by odds ratio (OR) and continuous data were calculated by weighed mean difference (WMD) with 95% confidence intervals (CI).
Results
A total of 11 studies (PSM=10; RCT=1) enrolling 2905 patients (AR = 1452; NAR=1453) with HCC were included in the present meta-analysis. For oncological outcomes, no significant differences were observed in disease-free survival (1 year: OR = 0.75, 95% CI:0.55∼1.03, P = 0.07; 3 year: OR = 0.85, 95% CI: 0.70∼1.03, P = 0.09; 5 year: OR = 0.87, 95% CI: 0.70∼1.10, P = 0.24) and overall survival (1 year: OR = 1.04, 95% CI:0.78∼1.38, P = 0.79; 3 year: OR = 0.88, 95% CI: 0.63∼1.23, P = 0.47; 5 year: OR = 0.82, 95% CI: 0.58∼1.17, P = 0.27) between the two groups. In addition, the pooled analysis suggested that no differences were found between the AR groups and NAR group with respect to operative time (WMD=17.98min, 95% CI: -2.18∼38.14, P = 0.08), blood loss (WMD=93.82ml, 95% CI: -32.68∼220.33, P = 0.15) and postoperative morbidity (OR = 0.88, 95% CI:0.57∼1.35, P = 0.55).
Conclusions
The present PSM and RCT data meta-analysis suggests that there does not appear to be a significant difference in survival between patients undergoing AR or NAR for HCC. Simultaneously, AR does not seem to bring more prognostic benefits in oncological outcomes including disease-free survival and overall survival. Considering unavoidable bias, more high-quality RCTs are badly needed to determine whether AR OR NAR can become standard practice for treating HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai is responsible for the governance, coordination and running of the study.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract